TGS


MHRA approves beremagene geperpavec (Vyjuvek) for the treatment of dystrophic epidermolysis bullosa

MHRA approves beremagene geperpavec (Vyjuvek) for the treatment of dystrophic epidermolysis bullosa

https://www.gov.uk/government/news/mhra-approves-beremagene-geperpavec-vyjuvek-for-the-treatment-of-dystrophic-epidermolysis-bullosa

seen at 20:43, 15 May in News and communications.